← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,318	+51	+2%	$293B
2	2 Merck MRK $358B	2,688	-22	-0.8%	$143B
3	3 Pfizer PFE $168B	2,676	0	0%	$133B
4	4 AbbVie ABBV $501B	2,615	+16	+0.6%	$128B
5	5 Bristol-Myers Squibb BMY $124B	2,370	+8	+0.3%	$103B
6	6 Amgen AMGN $235B	2,218	-3	-0.1%	$109B
7	7 Gilead Sciences GILD $195B	1,567	+4	+0.3%	$63.4B
8	8 Novartis NVS $286B	1,136	-41	-3%	$18.7B
9	9 Regeneron Pharmaceuticals REGN $82B	924	+20	+2%	$42.3B
10	10 GSK GSK $98.2B	776	-43	-5%	$11.3B
11	11 AstraZeneca AZN $259B	757	-31	-4%	$20.5B
12	12 DELISTED Exact Sciences EXAS	646	+23	+4%	$20.2B
13	SGEN 13 DELISTED Seagen Inc. Common Stock SGEN	501	-10	-2%	$22.3B
14	14 Incyte INCY $23B	493	-19	-4%	$16.5B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	441	+4	+0.9%	$8.74B
16	16 Guardant Health GH $22.3B	419	0	0%	$13.9B
17	17 Exelixis EXEL $15.6B	348	-4	-1%	$5.92B
18	18 Halozyme HALO $13.8B	336	-7	-2%	$5.52B
19	19 NeoGenomics NEO $2.22B	332	-8	-2%	$5.21B
20	20 Natera NTRA $58.3B	324	+20	+7%	$8.65B
21	21 Takeda Pharmaceutical TAK $62.1B	317	+4	+1%	$1.96B
22	22 Qiagen QGEN $9.53B	275	+6	+2%	$5.97B
23	23 DELISTED Blueprint Medicines BPMC	264	-15	-5%	$5.69B
24	24 Fate Therapeutics FATE $231M	260	+12	+5%	$7.73B
25	MRTX 25 DELISTED Mirati Therapeutics, Inc. Common Stock MRTX	260	-24	-8%	$9.16B